Literature DB >> 18263789

Significance of PRDM1beta expression as a prognostic marker in diffuse large B-cell lymphomas.

Wayne Tam, Mario Gomez, Kui Nie.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18263789     DOI: 10.1182/blood-2007-09-111385

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas.

Authors:  Katerina Vrzalikova; Martina Vockerodt; Sarah Leonard; Andrew Bell; Wenbin Wei; Alexandra Schrader; Kenneth L Wright; Dieter Kube; Martin Rowe; Ciaran B Woodman; Paul G Murray
Journal:  Blood       Date:  2011-03-16       Impact factor: 22.113

2.  Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1.

Authors:  Santiago Montes-Moreno; Nerea Martinez-Magunacelaya; Tomás Zecchini-Barrese; Sonia Gonzalez de Villambrosía; Emma Linares; Tamara Ranchal; María Rodriguez-Pinilla; Ana Batlle; Laura Cereceda-Company; Jose Bernardo Revert-Arce; Carmen Almaraz; Miguel A Piris
Journal:  Mod Pathol       Date:  2016-09-30       Impact factor: 7.842

3.  Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7.

Authors:  Kui Nie; Taotao Zhang; Hatim Allawi; Mario Gomez; Yifang Liu; Amy Chadburn; Y Lynn Wang; Daniel M Knowles; Wayne Tam
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

4.  Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma.

Authors:  Satoshi Ichikawa; Noriko Fukuhara; Hiroki Katsushima; Taro Takahashi; Joji Yamamoto; Hisayuki Yokoyama; Osamu Sasaki; Osamu Fukuhara; Jun Nomura; Kenichi Ishizawa; Ryo Ichinohasama; Akihiko Muto; Kazuhiko Igarashi; Hideo Harigae
Journal:  Cancer Sci       Date:  2014-03-08       Impact factor: 6.716

5.  EBV-miR-BHRF1-2 targets PRDM1/Blimp1: potential role in EBV lymphomagenesis.

Authors:  J Ma; K Nie; D Redmond; Y Liu; O Elemento; D M Knowles; W Tam
Journal:  Leukemia       Date:  2015-11-04       Impact factor: 11.528

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.